Humana Inc. (NYSE:HUM) had its price objective increased by analysts at Deutsche Bank AG from $234.00 to $243.00 in a research note issued on Monday. The firm presently has a “hold” rating on the insurance provider’s stock. Deutsche Bank AG’s price target points to a potential downside of 1.19% from the company’s previous close.

Several other brokerages also recently commented on HUM. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $237.00 price target on the stock in a report on Tuesday, April 18th. Jefferies Group LLC downgraded shares of Humana from a “buy” rating to a “hold” rating and cut their price target for the company from $237.00 to $221.00 in a report on Friday, April 21st. Cowen and Company reiterated an “outperform” rating and set a $230.00 price target on shares of Humana in a report on Tuesday, April 25th. Evercore ISI reiterated an “outperform” rating and set a $240.00 price target on shares of Humana in a report on Tuesday, April 25th. Finally, Cantor Fitzgerald upped their price target on shares of Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $243.00.

Humana (HUM) traded up 1.23% during midday trading on Monday, reaching $248.95. The company’s stock had a trading volume of 405,677 shares. Humana has a one year low of $163.50 and a one year high of $251.79. The firm has a market cap of $35.98 billion, a P/E ratio of 20.48 and a beta of 0.91. The firm has a 50 day moving average price of $236.19 and a 200 day moving average price of $220.68.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping the consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same quarter in the previous year, the company earned $2.30 EPS. Equities research analysts forecast that Humana will post $11.42 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/07/humana-inc-nysehum-price-target-raised-to-243-00.html.

In other Humana news, SVP Brian P. Leclaire sold 4,971 shares of the business’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the transaction, the senior vice president now owns 14,258 shares in the company, valued at approximately $3,421,920. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Heidi S. Margulis sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the transaction, the vice president now owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of HUM. Guardian Life Insurance Co. of America increased its stake in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after buying an additional 4 shares during the last quarter. Reliance Trust Co. of Delaware increased its stake in shares of Humana by 0.7% in the second quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock worth $270,000 after buying an additional 8 shares during the last quarter. Creative Planning increased its stake in shares of Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after buying an additional 15 shares during the last quarter. Cadence Capital Management LLC increased its stake in shares of Humana by 0.4% in the second quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock worth $1,367,000 after buying an additional 22 shares during the last quarter. Finally, Sit Investment Associates Inc. increased its stake in shares of Humana by 0.3% in the second quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after buying an additional 40 shares during the last quarter. Institutional investors and hedge funds own 99.66% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.